Javascript must be enabled to continue!
Use of Bevacizumab and Aflibercept in the Treatment of Diabetic Macular Edema: Cost-effectiveness Analysis
View through CrossRef
Background: The aim of this study was to evaluate the efficacy of aflibercept by comparison with bevacizumab in the treatment of diabetic macular edema.Methods: The study included 159 patients; the first group consisted of 58 patients who underwent intravitreal application of aflibercept, and the second group of 101 patients underwent intravitreal application of bevacizumab.Main Findings: There was a statistically significant decrease in edema during the optical coherence tomography (OCT) scans after the application of bevacizumab (533±152 μm vs. 384±104 μm, p<0.001) and aflibercept (500±110 μm vs. 354±80 μm, p<0.001). Moreover, a significant increase in central visual acuity was observed both for bevacizumab (0.29±0.20 μm vs. 0.36±0.22 μm, p<0.001) and aflibercept (0.40±0.30 μm vs. 0.48±0.31 μm, p<0.001). Principal Conclusion: Anintravitreal application of either aflibercept or bevacizumab resulted in a significant reduction in macular edema and a significant increase in central visual acuity. Although statistically more efficient, aflibercept use can hardly be justified, due to the high cost associated with its use. Bevacizumab achieved a higher cost-effectiveness compared with aflibercept. Therefore, its use should be considered depending on various healthcare systems, as well as socio-economic factors. Key words: diabetic retinopathy, diabetic macular edema, bevacizumab, aflibercept, optical coherence tomography, visual acuity
Title: Use of Bevacizumab and Aflibercept in the Treatment of Diabetic Macular Edema: Cost-effectiveness Analysis
Description:
Background: The aim of this study was to evaluate the efficacy of aflibercept by comparison with bevacizumab in the treatment of diabetic macular edema.
Methods: The study included 159 patients; the first group consisted of 58 patients who underwent intravitreal application of aflibercept, and the second group of 101 patients underwent intravitreal application of bevacizumab.
Main Findings: There was a statistically significant decrease in edema during the optical coherence tomography (OCT) scans after the application of bevacizumab (533±152 μm vs.
384±104 μm, p<0.
001) and aflibercept (500±110 μm vs.
354±80 μm, p<0.
001).
Moreover, a significant increase in central visual acuity was observed both for bevacizumab (0.
29±0.
20 μm vs.
0.
36±0.
22 μm, p<0.
001) and aflibercept (0.
40±0.
30 μm vs.
0.
48±0.
31 μm, p<0.
001).
Principal Conclusion: Anintravitreal application of either aflibercept or bevacizumab resulted in a significant reduction in macular edema and a significant increase in central visual acuity.
Although statistically more efficient, aflibercept use can hardly be justified, due to the high cost associated with its use.
Bevacizumab achieved a higher cost-effectiveness compared with aflibercept.
Therefore, its use should be considered depending on various healthcare systems, as well as socio-economic factors.
Key words: diabetic retinopathy, diabetic macular edema, bevacizumab, aflibercept, optical coherence tomography, visual acuity.
Related Results
Safety of intravitreal ziv-aflibercept in patients with diabetic macular edema, macular edema following retinal vein occlusion and neovascular age related macular degeneration in a Ghanaian population: A phase I randomized interventional study v1
Safety of intravitreal ziv-aflibercept in patients with diabetic macular edema, macular edema following retinal vein occlusion and neovascular age related macular degeneration in a Ghanaian population: A phase I randomized interventional study v1
Brief Background: Retinal vascular diseases are a significant cause of visual loss world-wide, including Ghana. Anti-vascular endothelial growth factor (anti-VEGF) such as afliberc...
Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular
Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular
ObjectiveThis study aimed to investigate and compare the efficacy and safety of retinal laser photocoagulation (PRP) alone, PRP with aflibercept 3+PRN, and PRP with aflibercept 5+P...
Treatment results switching from aflibercept to bevacizumab in wet age-related macular degeneration
Treatment results switching from aflibercept to bevacizumab in wet age-related macular degeneration
AIM: To examine effects of switching intravitreal aflibercept to bevacizumab in neovascular age-related macular degeneration (nAMD).
METHODS: Data from patients treated for nAMD wi...
Aflibercept or ranibizumab for the treatment of diabetic macular edema; a retrospective study
Aflibercept or ranibizumab for the treatment of diabetic macular edema; a retrospective study
Diabetic macular edema (DME) is a significant cause of diabetic retinopathy and a major cause of vision loss. In this study, we aimed to evaluate and compare the efficacy of two in...
Comparative Effectiveness of Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Diabetic Retinopathy Management
Comparative Effectiveness of Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Diabetic Retinopathy Management
Background: Anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard first-line treatment for
vision-threatening diabetic macular edema and selected severe diabe...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Reducing the Carbon Footprint of Neovascular Age–Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg
Reducing the Carbon Footprint of Neovascular Age–Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg
Purpose
To quantify and compare the carbon footprint associated with neovascular age–related macular degeneration (nAMD) treatment using real‐world intravitreal...
A Comparison of Visual Outcomes Between Patients Treated with Intravitreal Ranibizumab and Bevacizumab for Diabetic Macula Edema in A Real World Setting in Sub-Saharan Africa
A Comparison of Visual Outcomes Between Patients Treated with Intravitreal Ranibizumab and Bevacizumab for Diabetic Macula Edema in A Real World Setting in Sub-Saharan Africa
Aims and Objectives: To report a comparison of visual outcomes between patients treated with intravitreal ranibizumab and bevacizumab for diabetic macula oedema (DME) in a real-wor...

